Alveolar-Arterial Gradient Is an Early Marker to Predict Severe Pneumonia in COVID-19 Patients.

COVID-19 alveolar–arteriolar oxygen gradient severity marker

Journal

Infectious disease reports
ISSN: 2036-7430
Titre abrégé: Infect Dis Rep
Pays: Switzerland
ID NLM: 101537203

Informations de publication

Date de publication:
15 Jun 2022
Historique:
received: 02 05 2022
revised: 03 06 2022
accepted: 07 06 2022
entrez: 23 6 2022
pubmed: 24 6 2022
medline: 24 6 2022
Statut: epublish

Résumé

Background: One of the main challenges in the management of COVID-19 patients is to early assess and stratify them according to their risk of developing severe pneumonia. The alveolar−arterial oxygen gradient (D(A-a)O2) is defined as the difference between the alveolar and arteriolar concentration of oxygen, an accurate index of the ventilatory function. The aim of this study is to evaluate D(A-a)O2 as a marker for predicting severe pneumonia in COVID-19 patients, in comparison to the PaO2/FiO2. Methods: This retrospective, multicentric cohort study included COVID-19 patients admitted to two Italian hospitals between April and July 2020. Clinical and laboratory data were retrospectively collected at the time of hospital admission and during hospitalization. The presence of severe COVID-19 pneumonia was evaluated, as defined by the Infectious Diseases Society of America (IDSA) criteria for community-acquired pneumonia (CAP). Patients were divided in severe and non-severe groups. Results: Overall, 53 COVID-19 patients were included in the study: male were 30/53 (57%), and 10/53 (19%) had severe pneumonia. Patients with severe pneumonia reported dyspnea more often than non-severe patients (90% vs. 39.5%; p = 0.031). A history of chronic obstructive pulmonary disease (COPD) was recalled by 5/10 (50%) patients with severe pneumonia, and only in 6/43 (1.4%) of non-severe cases (p = 0.023). A ROC curve, for D(A-a)O2 >60 mmHg in detecting severe pneumonia, showed an area under the curve (AUC) of 0.877 (95% CI: 0.675−1), while the AUC of PaO2/FiO2 < 263 mmHg resulted 0.802 (95% CI: 0.544−1). D(A-a)O2 in comparison to PaO2/FiO2 had a higher sensibility (77.8% vs. 66.7%), positive predictive value (75% vs. 71.4%), negative predictive value (94% vs. 91%), and similar specificity (94.4% vs. 95.5%). Conclusions: Our study suggests that the D(A-a)O2 is more appropriate than PaO2/FiO2 to identify COVID-19 patients at risk of developing severe pneumonia early.

Identifiants

pubmed: 35735760
pii: idr14030050
doi: 10.3390/idr14030050
pmc: PMC9222321
doi:

Types de publication

Journal Article

Langues

eng

Pagination

470-478

Références

N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
J Thromb Haemost. 2020 Apr;18(4):844-847
pubmed: 32073213
Monaldi Arch Chest Dis. 2020 Jul 15;90(3):
pubmed: 32672430
Cureus. 2020 Nov 7;12(11):e11368
pubmed: 33304701
Rev Saude Publica. 2020;54:60
pubmed: 32491116
JAMA. 2012 Jun 20;307(23):2526-33
pubmed: 22797452
Diagnostics (Basel). 2021 Apr 23;11(5):
pubmed: 33922829
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
Eur J Intern Med. 2021 Oct;92:48-54
pubmed: 34175182
EClinicalMedicine. 2021 May 16;35:100879
pubmed: 34041456
Arch Acad Emerg Med. 2022 Apr 14;10(1):e28
pubmed: 35573712
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Crit Care Med. 2021 Mar 1;49(3):e219-e234
pubmed: 33555780
Lancet. 2018 Apr 28;391(10131):1693-1705
pubmed: 29726345
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Invest Radiol. 2020 Jun;55(6):327-331
pubmed: 32118615
Crit Care. 2014 Dec 23;18(6):711
pubmed: 25532567
Int J Infect Dis. 2021 Jul;108:244-251
pubmed: 34023492
Intensive Care Med. 2020 May;46(5):846-848
pubmed: 32125452
JAMA Netw Open. 2020 Sep 1;3(9):e2022310
pubmed: 32965502
Am J Respir Crit Care Med. 2019 Oct 1;200(7):e45-e67
pubmed: 31573350
Allergy. 2021 Feb;76(2):428-455
pubmed: 33185910
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
J Infect. 2020 Apr;80(4):401-406
pubmed: 32112886
Nature. 2020 Dec;588(7837):315-320
pubmed: 32846427
ERJ Open Res. 2021 Mar 08;7(1):
pubmed: 33718488
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
BMC Pulm Med. 2019 Feb 26;19(1):53
pubmed: 30808337

Auteurs

Giuseppe Pipitone (G)

Infectious Disease Unit, ARNAS Civico-Di Cristina, Piazza Leotta 5, 90100 Palermo, Italy.
National Institute of Infectious Diseases Lazzaro Spallanzani, Via Portuense 292, 00149 Rome, Italy.

Marta Camici (M)

National Institute of Infectious Diseases Lazzaro Spallanzani, Via Portuense 292, 00149 Rome, Italy.

Guido Granata (G)

National Institute of Infectious Diseases Lazzaro Spallanzani, Via Portuense 292, 00149 Rome, Italy.

Adriana Sanfilippo (A)

Infectious Disease Unit, ARNAS Civico-Di Cristina, Piazza Leotta 5, 90100 Palermo, Italy.

Francesco Di Lorenzo (F)

Infectious Disease Unit, ARNAS Civico-Di Cristina, Piazza Leotta 5, 90100 Palermo, Italy.

Calogero Buscemi (C)

Infectious Disease Unit, ARNAS Civico-Di Cristina, Piazza Leotta 5, 90100 Palermo, Italy.

Antonio Ficalora (A)

Infectious Disease Unit, ARNAS Civico-Di Cristina, Piazza Leotta 5, 90100 Palermo, Italy.

Daria Spicola (D)

Infectious Disease Unit, ARNAS Civico-Di Cristina, Piazza Leotta 5, 90100 Palermo, Italy.

Claudia Imburgia (C)

Infectious Disease Unit, ARNAS Civico-Di Cristina, Piazza Leotta 5, 90100 Palermo, Italy.

Ilenia Alongi (I)

Infectious Disease Unit, ARNAS Civico-Di Cristina, Piazza Leotta 5, 90100 Palermo, Italy.

Francesco Onorato (F)

Infectious Disease Unit, ARNAS Civico-Di Cristina, Piazza Leotta 5, 90100 Palermo, Italy.

Caterina Sagnelli (C)

Infectious Disease Unit, University Hospital Luigi Vanvitelli, Vico Luigi De Crecchio, 80138 Naples, Italy.

Chiara Iaria (C)

Infectious Disease Unit, ARNAS Civico-Di Cristina, Piazza Leotta 5, 90100 Palermo, Italy.

Classifications MeSH